작성자 : 베데스다병원

요약 :
Mesenchymal stem cells (MSCs) are known to have a potential for articular cartilage regeneration. However, most studies focused on focal cartilage defect through surgical implantation. For the treatment of generalized cartilage loss in osteoarthritis, an alternative delivery strategy would be more appropriate. The purpose of this study was to assess the safety and efficacy of intra-articular injection of autologous adipose tissue derived MSCs (AD-MSCs) for knee osteoarthritis. We enrolled 18 patients with osteoarthritis of the knee and injected AD MSCs into the knee. The phase I study consists of three dose-escalation cohorts; the low-dose (1.0 3 107 cells), mid-dose (5.0 3 107), and high-dose (1.0 3 108) group with three patients each. The phase II included nine patients receiving the high-dose. The primary outcomes were the safety and the Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) at 6 months. Secondary outcomes included clinical, radiological, arthroscopic, and histological evaluations. There was no treatment-related adverse event.
The WOMAC score improved at 6 months after injection in the high-dose group. The size of cartilage defect decreased while the volume of cartilage increased in the medial femoral and tibial condyles of the high-dose group. Arthroscopy showed that the size of cartilage defect decreased in the medial femoral and medial tibial condyles of the high-dose group. Histology demonstrated thick, hyaline-like cartilage regeneration. These results showed that intra-articular injection of 1.0 3 108 AD MSCs into the osteoarthritic knee improved function and pain of the knee joint without causing adverse events, and reduced cartilage defects by regeneration of hyaline-like articular cartilage

요약 : 
A 5-year-old castrated male Chihuahua weighing 1.54 kg was examined because of a several month history of progressive right hind limb lameness. Physical examination of the stifle joints revealed pain and a grade IV medial patellar luxation on the right stifle joint. The right and left stifle joints were associated with a lameness of grade 2 and grade 0, respectively. Radiography revealed osteophytes or subchondral cystic lesions on the right and left stifle joints. Osteoarthrosis (OA) scores for the right and left stifle joints were 20 and 12 respectively. Combination of surgery and implantation of autologous adipose tissue derived mesenchymal stem cells (aAT-MSCs) was determined with informed consent. 1 × 106 aAT-MSCs suspended in PBS and 0.6 mL of hyaluronic acid were injected in the right stifle joint postoperatively. Osteoarthrosis scores and the lameness grade for the right and left stifle joints were 19 and 13, and 0 and 0 19 months after treatment, respectively, and 14 and 15, and 0 and 0 five years after treatment, respectively. This case report shows radiographical evidence of a decrease in osteophytes and subchondral cystic lesions on the stifle joint with OA after aAT-MSCs injection.

요약 : 
Human adipose tissue-derived mesenchymal stem cell (hATMSC) have emerged as a potentially powerful tool for bone repair, but an appropriate evaluation system has not been established. The purpose of this study was to establish a preclinical assessment system to evaluate the efficacy and safety of cell therapies in a nude rat bone defect model. Segmental defects (5 mm) were created in the femoral diaphyses and transplanted with
cell media (control), hydroxyapatite/tricalcium phosphate scaffolds (HA/TCP, Group I), hATMSCs (Group II), or three cell-loading density of hATMSC-loaded HA/TCP (Group III-V). Healing response was evaluated by serial radiography, micro-computed tomography and histology at 16 weeks. To address safety-concerns, we conducted a GLP-compliant toxicity study. Scanning electron microscopy studies showed that hATMSCs filled the pores/surfaces of scaffolds in a cell-loading density-dependent manner. We detected significant increases in bone formation in the hATMSC-loaded HA/TCP groups compared with other groups. The amount of new bone formation increased with increases in loaded cell number. In a toxicity study, no significant hATMSC-related changes were found in body weights, clinical signs, hematological/biochemical values, organ weights, or histopathological findings. In conclusion, hATMSCs loaded on HA/TCP enhance the repair of bone defects and was found to be safe under our preclinical efficacy/safety hybrid assessment system.

요약 : 
Rheumatoid arthritis is a chronic autoimmune disease and affecting approximately 1% of the population. Human adipose-derived mesenchymal stem cells (hASCs) were recently found to suppress effector T cell and inflammatory responses and, thus, to have beneficial effects in various autoimmune diseases. In this study, we examined whether hASCs could play a protective and/or therapeutic role in collagen-induced arthritis (CIA). We showed that hASCs both prevented and treated CIA by significantly reducing the incidence and severity of experimental arthritis. We further demonstrated that treatment with hASCs inhibited the production of various inflammatory mediators, decreased antigen-specific Th1/Th17 cell expansion, and induced the production of anti-inflammatory cytokine interleukin-10. Moreover, hASCs could induce the generation of antigen-specific Treg cells with the capacity to suppress collagen-specific T cell responses.

본 특허는 태반 조직 유래 다능성 줄기세포 및 이를 함유하는 세포치료제에 관한 것으로, 보다 구체적으로는, 세절한 양막, 장막, 기저탈락막 또는 태반 조직을 bFGF 함유 배지에서 배양한 다음 회수하는 것을 특징으로 하는,
(a) CD29, CD44, CD73, CD90 및 CD105에 대하여 모두 양성의 면역학적 특성을 나타내고,　CD31, CD34, CD45 및 HLA-DR에 대하여 모두 음성의 면역학적 특성을 나타냄;
(b) Oct4 및 SSEA4에 대하여 양성의 면역학적 특성을 나타냄;
(c) 플라스틱에 부착되어 성장하며, 둥근형태(round-shape) 또는 선형태(spindle-shape)의 형태학적 특성을 나타내고, SFM 배지(sphere-forming medium)에서 스피어(sphere)를 형성하여 미분화 상태로 장기간 유지가 가능함;
(d) 중배엽, 내배엽 및 외배엽 유래 세포로 분화하는 능력을 가지는 태반 줄기세포의 제조 방법 및 수득된 태반 줄기세포에 관한 것이다.

본 발명에 따른 다능성 줄기세포는 근세포, 혈관내피세포, 골형성 세포, 신경세포, 성상세포, 지방세포, 연골형성 세포, 골형성 세포, 또는 인슐린 분비 췌장 베타세포로 분화하는 능력을 가지고 있어, 근질환, 골다공증, 골관절염, 신경질환, 당뇨병 등의 치료에 효과적이고, 유방 조직 형성에 유용하다.

본 특허는 탈락막 또는 지방 유래 줄기세포를 함유하는 요실금의 세포치료제에 관한 것으로, 보다 구체적으로는, 태반이나 생리혈의 탈락막 유래 줄기세포 또는 지방 유래 줄기세포를 함유하는 요실금의 세포치료제에 관한 것이다.
본 특허에 따른 탈락막 또는 지방 유래 줄기세포는 요누출압 증가 및 요도괄약근 수축력을 향상시키는 효과를 나타내므로 요실금 치료제로서 유용하다.

본 발명은 항바이러스 활성을 나타내는 백화사설초 및 영지버섯 추출물을 포함하는 조성물에 관한 것으로서, 더욱 상세하게는, PMWS 바이러스, PRRS 바이러스, PED 바이러스, TGE 바이러스, 파보 바이러스 및 디스템퍼 바이러스에 대해 우수한 항바이러스 활성을 나타내는 백화사설초 및 영지버섯 추출물을 유효성분으로 함유하는 약학조성물에 관한 것이다.

본 발명은 이솔리퀴리틴을 함유하는 유방암 예방용 식품에 관한 것으로, 본 발명의 이솔리퀴리틴은 에스트로젠성은 나타내나 안드로젠성은 나타내지 않고, 내분비계 장애물질인 비스페놀-A의 활성을 억제하며, 유방암 세포를 비롯한 암 세포의 증식을 저해하므로, 파이토에스트로젠으로서 호르몬 대체 치료 및 유방암의 예방 및 치료를 위해 사용될 수 있다.

본 발명은 인진쑥( Artemisia capillaris thunberg. ), 마늘 및 오가피( Acanthopanax ) 추출물을 포함하는 사료조성물을 이용한 올레인산 강화 닭고기의 제조방법 및 올레인산이 강화된 기능성 닭고기에 관한 것이다.

본 발명은 상사화 추출물을 함유하는 항바이러스 조성물에 관한 것으로서, 더욱 상세하게는, 인간, 돼지, 말, 조류 등을 감염시키는 인플루엔자 바이러스(influenza virus) 질환의 예방 또는 치료용 조성물에 관한 것이다.